CurrentAetnaPolicy 0515

Thyrogen (Thyrotropin Alfa)

Clinical coverage policy for Thyrogen (thyrotropin alfa) for commercial medical plans, detailing indications, dosing, experimental uses, and applicable coding; affects providers ordering/administering Thyrogen for patients with differentiated thyroid carcinoma and nontoxic multinodular goiter.

Policy Summary

PayerAetna

PolicyThyrogen (Thyrotropin Alfa)

Policy CodePolicy 0515

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain prior authorization for Thyrogen (HCPCS J3240) when used for Tg testing or radioiodine imaging as an alternative to thyroid hormone withdrawal.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6RCTs in meta-analysis

J3240Covered HCPCS

C73, E04.2, Z85.850Covered ICD-10

7–37NNT range

Coverage Criteria for Thyrogen (thyrotropin alfa)

Evidence summaries

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

ALL of the following

Randomized trials comparing rhTSH (Thyrogen) preparation versus thyroid hormone withdrawal (THW) for radioiodine remnant ablation (RRA) show comparable ablation success rates at 6–12 months. Pacini et al (2006) reported similar remnant ablation (96% rhTSH vs 86% THW; p=0.23) and improved quality of life and lower blood radiation exposure with rhTSH.
Source: chunk11
A 2014 systematic review and meta-analysis (Pak et al) of 6 randomized trials (1,660 patients) found no significant differences in ablation success between rhTSH and THW across multiple definitions of success (Tg cut-offs of 1 or 2 ng/mL and imaging-based definitions).
Source: chunk18
For facilitation of RAI ablation after surgery, randomized data support that rhTSH is an effective alternative to thyroid hormone withdrawal, with comparable ablation outcomes and improved patient-reported quality of life during preparation.
Sources: chunk11, chunk18
rhTSH as an adjunct to radioiodine therapy for benign non-toxic multinodular goiter: Two randomized, double-blind placebo-controlled trials (Fast et al, pooled n=86) with long-term follow-up (median ~71 months) demonstrated greater goiter volume reduction and improved goiter-related symptoms with rhTSH-augmented (131)I therapy versus (131)I alone, but with higher rates of hypothyroidism in the rhTSH group. Additional therapy was required less often in the rhTSH group (2/42 vs 9/44).
Source: chunk15
Safety and long-term outcomes: A 2023 meta-analysis (Sunavala-Dossabhoy & Petti) examining long-term salivary gland dysfunction (LT-SGD) after RAI found pooled relative risks suggesting reduced LT-SGD with rhTSH preparation versus THW (fixed-effect RR 0.65; random-effects RR 0.62, with some models crossing unity). Stratified results suggested protection at higher RAI activities (>=3.7 GBq RR 0.75; 95% CI 0.57–0.98). The authors judged evidence moderate quality that rhTSH may protect salivary gland function.
Sources: chunk21, chunk22
In patients with suppressed Tg (<0.1 ng/mL on T4 suppression), rhTSH-stimulated thyroglobulin testing has limited additional utility: Chindris et al (2012) found most such patients remain undetectable or minimally increased after stimulation and that periodic suppressed Tg and neck ultrasound adequately detected recurrences; rhTSH testing did not change management in this group.
Source: chunk17
Evidence on benign thyroid nodules: Small study data (Bountouris et al, 2023) indicate transient increases in nodule and thyroid parenchyma volume 48 hours after a low 0.3 mg dose of rhTSH, with volumes returning to baseline by 6 months; responses were heterogeneous. Clinical benefit for benign nodules remains uncertain.
Source: chunk19

Coding and Diagnosis Codes

Covered CPT/HCPCS related to testing and ThyrogenmixedCovered

78012	Thyroid uptake, single or multiple quantitative measurement(s) (including stimulation, suppression, or discharge, when performed).
78013	Thyroid imaging (including vascular flow, when performed).
78014	with single or multiple uptake(s) quantitative measurement(s) (including stimulation, suppression, or discharge, when performed).
78015-78018	Thyroid carcinoma metastases imaging.
78020	Thyroid carcinoma metastases uptake (List separately in addition to code for primary procedure).
80418	Combined rapid anterior pituitary evaluation panel.
80438	Thyrotropin releasing hormone (TRH) stimulation panel; one hour.
80439	TRH stimulation panel; two hour.
84432	Thyroglobulin.
84443	Thyroid stimulating hormone (TSH).

1–10 of 11

1/2

ICD-10 codes covered if selection criteria are metICD-10Covered

C73	Malignant neoplasm of thyroid gland [except for suppressed serum thyroglobulin (less than 0.1 ng/ml)].
E04.2	Nontoxic multinodular goiter [adjunct to radioiodine ablation].
Z85.850	Personal history of malignant neoplasm of thyroid.

Suppressed thyroglobulin threshold

Numeric thresholdSuppressed thyroglobulin defined as < 0.1 ng/mL

Clinical implicationUtility of rhTSH testing is limited when Tg-suppressed is < 0.1 ng/mL; may not change management

Source studyChindris et al (2012) assessed patients with Tg-supp < 0.1 ng/mL showing most remained undetectable after rhTSH

Provider Actions, Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization required for Thyrogen (J3240) when used for thyroglobulin (Tg) testing and radioiodine imaging in place of thyroid hormone withdrawal — ensure authorization is obtained before administration.

Affected code: J3240 (Injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vial)
Indications requiring prior auth: Tg testing and radioiodine imaging as an alternative to thyroid hormone withdrawal for differentiated thyroid carcinoma; facilitation of radioiodine ablation after surgery; adjunct to radioiodine ablation for non-toxic multinodular goiter.

Step Therapy

Step Therapy / Standard Alternative

Step therapy: thyroid hormone withdrawal (THW) remains the standard diagnostic modality and is the preferred/standard alternative. Use of Thyrogen (thyrotropin alfa) is appropriate when THW is contraindicated, not acceptable to the member, or the member is unable to mount an adequate endogenous TSH response. Document clinical rationale for using Thyrogen instead of THW.

Standard alternative: thyroid hormone withdrawal (THW)
When Thyrogen may be used instead: contraindication to THW, patient unwilling to undergo THW and physician justification, inadequate endogenous TSH response, or to avoid sole reliance on Tg testing without withdrawal.

Note

No Explicit Step Therapy Requirements

No additional step therapy requirements are specified beyond the preference for thyroid hormone withdrawal as the standard diagnostic approach. There are no described mandated trial durations or fail-first numeric thresholds in the provided policy text.

Policy does not list mandatory step-fail timeframes or numeric thresholds prior to Thyrogen use.

Documentation Required

Required Clinical Documentation

Required clinical documentation should include diagnosis codes supporting the indication (e.g., C73, E04.2, Z85.850), clinical rationale for using Thyrogen instead of thyroid hormone withdrawal (contraindication, patient refusal, inadequate TSH response, undetectable Tg on suppressive therapy), and relevant test results (serum Tg, TSH levels, anti-Tg antibody status) and treatment history (thyroidectomy, prior radioiodine ablation). Include dosing plan (two 0.9 mg IM injections 24 hours apart) and ordering/provider information.

Suggested ICD-10 codes: C73 (malignant neoplasm of thyroid), E04.2 (nontoxic multinodular goiter), Z85.850 (personal history of malignant neoplasm of thyroid)
Document: clinical justification for avoiding THW, serum Tg and TSH results, anti-Tg antibody status, prior treatments, and planned Thyrogen dosing regimen.

Denial Risk

Experimental/Investigational — Denial Risk

Use of thyrotropin alfa for indications not listed as medically necessary (for example, in individuals with suppressed serum thyroglobulin <0.1 ng/mL or other unapproved uses) is considered experimental/investigational and may lead to denial of coverage.

Experimental/Investigational — denial risk: any indication outside the approved/medically necessary uses described in the policy (e.g., suppressed serum Tg <0.1 ng/mL).

Background and Scope

Thyrogen (recombinant human thyroid‑stimulating hormone, rhTSH) is FDA‑approved as an adjunctive diagnostic agent to facilitate serum thyroglobulin testing with or without radioiodine imaging in the follow‑up of well‑differentiated thyroid cancer, and as an adjunct to radioiodine remnant ablation after thyroidectomy. It stimulates thyroglobulin production and radioiodine uptake so that testing or ablation can often be performed without thyroid hormone withdrawal, thereby avoiding the hypothyroid period associated with withdrawal. Limitations noted in the policy include lower sensitivity compared with withdrawal in some settings and potential assay confounding by anti‑thyroglobulin antibodies; clinical use should follow the policy’s covered indications and documentation requirements.

Definitions and Abbreviations

Thyrogen (thyrotropin alfa) — definition and mechanism

DefinitionRecombinant form of thyroid-stimulating hormone (thyrotropin alfa) used to stimulate thyroglobulin production and radioiodine uptake

Primary approved usesAdjunctive diagnostic tool for serum thyroglobulin testing with or without radioiodine imaging in follow-up of well-differentiated thyroid cancer; adjunct for radioiodine remnant ablation

MechanismStimulates thyroid tissue to produce thyroglobulin and increase radioiodine uptake, allowing testing or ablation without thyroid hormone withdrawal

Suppressed serum thyroglobulin — definition and clinical threshold

DefinitionSuppressed serum thyroglobulin: thyroglobulin level maintained below 0.1 ng/mL while on thyroid hormone suppression therapy

Clinical noteIn patients with DTC whose T4-suppressed serum Tg is < 0.1 ng/mL, rhTSH testing generally does not change management; long-term monitoring with annual Tg-supp and periodic neck ultrasound is adequate

Observed response to rhTSHAfter rhTSH stimulation many patients with Tg-supp < 0.1 ng/mL remain < 0.1 ng/mL, with only a minority showing clinically significant increases

RRA — radioiodine remnant ablation definition

DefinitionRadioiodine remnant ablation (RRA): radioactive iodine treatment administered after thyroidectomy to ablate residual thyroid tissue

Use contextRRA can be prepared either by thyroid hormone withdrawal (THW) or by recombinant human TSH (rhTSH/Thyrogen); randomized trials show comparable ablation success

Trial evidenceMeta-analysis of 6 randomized trials (1,660 patients) found similar ablation success with rhTSH versus THW

LT-SGD — long-term salivary gland dysfunction definition

DefinitionLong-term salivary gland dysfunction (LT-SGD): persistent salivary gland impairment occurring 1 year or more after radioactive iodine therapy

Effect of preparationMeta-analysis suggests rhTSH preparation is associated with reduced LT-SGD compared with THW-prepared patients (pooled RRs around 0.65–0.80 depending on model)

Evidence summaryFive studies (321 rhTSH, 632 THW) included in pooled analysis; subgroup analyses considered RAI activity levels